10026-13-8Relevant articles and documents
Baxter, G. P.,Moore, C. J.
, p. 1644 - 1657 (1912)
Groeneveld, W. L.,Visser, J. H.,Seuter, A. M. J. H.
, p. 245 - 248 (1958)
Glemser, O.,Wyszomirski, E.
, p. 25 - 25 (1961)
Holroyd, G. W. F.,Chadwick, H.,Mitchell, J. E. H.
, p. 2492 - 2493 (1925)
Popov, I. A.,Geske, D. H.,Baenziger, N. C.
, p. 1793 - 1796 (1956)
Downs, J.,Johnson, R. E.
, p. 143 - 144 (1954)
Heterocyclic dihydropyrimidine compounds
-
, (2008/06/13)
Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
Muscarinic receptor agonists
-
, (2008/06/13)
This invention relates to a novel class of partial or full muscarinic receptor agonists intermediates for their preparation, and pharmaceutical compositions and methods of use for the treatment or prevention of diseases the treatment or prevention of whic